All valid questions. The company decided to destroy the stock first and answer questions later. I think people were only holding for efficacy data in humans.
They need funding and a partner for Hep B. Will they achieve this without human efficacy.
The stock is a startup shell now. I am at a loss in every way imaginable. There will be some in-vivo data out next month for Heb b. Wait for this? What we trading at on a pre-consolidation basis? 1 cent or less?
Take over target? I'd even take 30 cents right now.
9 patients dosed. How may Cohort 4 patients is this? Still just 1?
Ann: UPDATE ON HCV CLINICAL TRIAL, page-74
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)